Letter ·
NAMD Provides Thoughts on High-Cost Drugs to Senate Finance
In March 2016, NAMD responded to a Senate Finance Committee Request for Information on prescription drug costs and coverage.
In March 2016, NAMD responded to a series of questions from the Senate Finance Committee on how to account for value in the pricing and coverage of breakthrough prescription drug therapies. The letter outlines potential policy options for improving the Medicaid Drug Rebate Program and other options to grant states additional tools for managing the impact of these drugs on the Medicaid program.
Related resources
NAMD Comments on Proposed Rule that Would Require Medicaid Coverage of Anti-Obesity Medications
In December 2024, CMS issued a proposed rule that would require Medicaid to cover anti-obesity medications.
Breaking the Bottleneck: Modernizing Medicaid Drug Access in the Million Dollar Therapy Era
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.